Extrapolation of trial results suggests that aspirin is useful in intermittent claudication.
作者信息
Gresele P, Migliacci R
出版信息
BMJ. 1998 Dec 5;317(7172):1587-8. doi: 10.1136/bmj.317.7172.1587a.
Abstract
摘要
相似文献
1
Extrapolation of trial results suggests that aspirin is useful in intermittent claudication.试验结果的推断表明阿司匹林在间歇性跛行中有用。
BMJ. 1998 Dec 5;317(7172):1587-8. doi: 10.1136/bmj.317.7172.1587a.
2
Variability in responsiveness to clopidogrel in patients with intermittent claudication.间歇性跛行患者对氯吡格雷反应的变异性。
Eur J Vasc Endovasc Surg. 2006 Jul;32(1):71-5. doi: 10.1016/j.ejvs.2006.01.013. Epub 2006 Mar 23.
3
Effect of cloricromene on intermittent claudication. A randomized, double-blind, placebo-controlled trial in patients treated with aspirin: effect on claudication distance and quality of life. CRAMPS Investigator Group. Cloricromene Randomized Arteriopathy Multicenter Prospective Study.氯克罗孟对间歇性跛行的影响。一项在服用阿司匹林的患者中进行的随机、双盲、安慰剂对照试验：对跛行距离和生活质量的影响。CRAMPS研究组。氯克罗孟随机动脉病多中心前瞻性研究。
Vasc Med. 2000;5(2):83-9. doi: 10.1177/1358836X0000500204.
4
Treatment of intermittent claudication with antiplatelet agents.使用抗血小板药物治疗间歇性跛行。
J Int Med Res. 1990 Sep-Oct;18(5):400-7. doi: 10.1177/030006059001800508.
5
6
Identification of aspirin resistance using a PDW-miR92a-score: Validation in an intermittent claudication cohort.使用血小板分布宽度- miR92a评分识别阿司匹林抵抗：在间歇性跛行队列中的验证
Clin Biochem. 2019 Feb;64:30-36. doi: 10.1016/j.clinbiochem.2018.12.009. Epub 2018 Dec 23.
7
A comparison between aspirin and pentoxifylline in relieving claudication due to peripheral vascular disease in the elderly.阿司匹林与己酮可可碱缓解老年外周血管疾病所致间歇性跛行的比较。
Angiology. 1997 Mar;48(3):237-40. doi: 10.1177/000331979704800306.
8
[Role of antiaggregants in the treatment of arterial diseases of the lower limbs].[抗血小板聚集剂在下肢动脉疾病治疗中的作用]
Arch Mal Coeur Vaiss. 1991 Nov;84(11 Suppl):1721-4.
9
Rationale for the use of antiplatelet drugs in patients with peripheral vascular disease.
Clin Trials Metaanal. 1994 Apr;29(1):81-7.
10
Cilostazol: treatment of intermittent claudication.西洛他唑：治疗间歇性跛行。
Ann Pharmacother. 2001 Jan;35(1):48-56. doi: 10.1345/aph.19408.
本文引用的文献
1
Targeting subclinical atherosclerosis. Has the potential to reduce coronary events dramatically.针对亚临床动脉粥样硬化。有可能显著降低冠心病事件。
BMJ. 1998 Jun 13;316(7147):1764. doi: 10.1136/bmj.316.7147.1764.
2
North of England evidence based guideline development project: guideline on the use of aspirin as secondary prophylaxis for vascular disease in primary care. North of England Aspirin Guideline Development Group.英格兰北部循证指南制定项目：初级保健中阿司匹林用于血管疾病二级预防的指南。英格兰北部阿司匹林指南制定小组。
BMJ. 1998 Apr 25;316(7140):1303-9. doi: 10.1136/bmj.316.7140.1303.
3
Thrombosis prevention trial: randomised trial of low-intensity oral anticoagulation with warfarin and low-dose aspirin in the primary prevention of ischaemic heart disease in men at increased risk. The Medical Research Council's General Practice Research Framework.血栓形成预防试验：对高危男性采用华法林进行低强度口服抗凝治疗与小剂量阿司匹林用于缺血性心脏病一级预防的随机试验。医学研究委员会全科医学研究框架。
Lancet. 1998 Jan 24;351(9098):233-41.
4
Collaborative overview of randomised trials of antiplatelet therapy--I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Antiplatelet Trialists' Collaboration.抗血小板治疗随机试验的协作综述——I：各类患者长期抗血小板治疗预防死亡、心肌梗死和中风。抗血小板试验协作组。
BMJ. 1994 Jan 8;308(6921):81-106.
5
Aspirin after myocardial infarction.
Lancet. 1980 May 31;1(8179):1172-3.
Zotero 插件